Clene Inc. Form 8-K Summary
Business Context and Reporting Period
Clene Inc. filed a Current Report on Form 8-K dated August 5, 2021, reporting corporate governance and director appointment matters. The filing does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- On August 5, 2021, the Board appointed Vallerie V. McLaughlin, M.D. as an independent Class III director.
- Dr. McLaughlin will serve through the 2024 Annual Meeting of Stockholders and until her successor is elected and qualified.
- She was also appointed to the Nominating and Corporate Governance Committee, becoming its third member.
Compensation, Outlook, and Other Matters
- Dr. McLaughlin received options for 45,000 common shares at an exercise price of $9.37, equal to the August 5, 2021 Nasdaq closing price. The options vest in 36 equal monthly installments beginning August 31, 2021.
- She also received immediately vested options with a Black-Scholes equivalent value of $10,000 for Board service and $1,000 for Nominating and Corporate Governance Committee service, also at a $9.37 exercise price. The filing text does not provide the number of shares underlying these awards.
- The filing states that there were no arrangements or understandings relating to the appointment and no reportable related-party transactions under Item 404(a) of Regulation S-K.
- The company issued a related press release, filed as Exhibit 99.1. No financial guidance, business outlook, contingencies, or unusual operating items were disclosed.
Important Facts to Verify
- Confirm the vesting schedule and final share count for the Black-Scholes-based Board and committee option awards.
- Review Exhibit 99.1 for additional information concerning Dr. McLaughlin’s appointment and qualifications.
- Assess the impact of the director option grants on future share dilution and stock-based compensation.
- Consult subsequent filings for any changes to Board composition, committee membership, or director compensation.